NCT01818661 · Phase 4 · RECRUITING
Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech
This study uses brain scans, including a PET scan with a tracer drug called AV-1451 that highlights tau protein, to follow people with progressive apraxia of speech over time. It looks at how brain changes line up with changes in speech and thinking. It is a Phase 4 imaging study, not a test of a therapy.
You may qualify if
- We will study subjects that fulfill clinical inclusion criteria for neurodegenerative AOS that have been seen and diagnosed at Mayo Clinic
You're excluded if
- Subjects with concurrent illnesses that could account for speech and language deficits, such as traumatic brain injury, strokes or developmental syndromes will be excluded.
- Women that are pregnant or post-partum and breast-feeding will be excluded. All women who can become pregnant must have a pregnancy test no more than 48 hours before the PET scan.
- Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism,(e.g. chemotherapy).
- Subjects will also be excluded if they do not have an informant, or do not consent to research.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-11-12